Epithalon
NeuroprotectionNeurology research on Epithalon examines whether this pineal-derived tetrapeptide produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: identified by khavinson in st petersburg. stimulates telomerase activity in somatic cells, with downstream effects on telomere length over multi-year cycles. normalises age-related decline in pineal melatonin output. putative epigenetic effects on aging-clock methylation patterns are an active area of investigation.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. Epithalon is dosed at 5-10 mg 1x daily for 10-20 day cycles, 1-2x yearly via subq/intranasal in cognitive-focused protocols, with the Very short (minutes) pharmacokinetic profile shaping receptor occupancy timing.
Key Takeaways
Cognitive lens: Epithalon acts as a modulator with both restorative and modest activating components for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: Identified by Khavinson in St. Neuro dose: 5-10 mg 1x daily for 10-20 day cycles, 1-2x yearly via subq/intranasal; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
Identified by Khavinson in St. Petersburg. Stimulates telomerase activity in somatic cells, with downstream effects on telomere length over multi-year cycles. Normalises age-related decline in pineal melatonin output. Putative epigenetic effects on aging-clock methylation patterns are an active area of investigation. For cognitive endpoints specifically, this mechanism translates into restorative rather than stimulant effects: reduction of neuroinflammation, support for BDNF and NGF signalling, modulation of monoamine systems, and stabilisation of cerebral perfusion. The three subsections below examine Epithalon's CNS access route, the neurotrophic and inflammatory effects, and the receptor-level pharmacology.
Cerebral perfusion and the structural cognitive substrate
Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. Epithalon, with its Identified by Khavinson in St Petersburg. Stimulates telomerase activity in somatic cells, with downstream effects on telomere length over multi-year cycles. Normalises age-related decline in pineal melatonin output. Putative epigenetic effects on aging-clock methylation patterns are an active area of investigation. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The Very short (minutes) pharmacokinetic profile supports this restorative rather than stimulant phenotype.
Inflammation and neurological recovery
One of the most replicated effects across compounds in Epithalon's class (Pineal-derived tetrapeptide) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. Epithalon's contribution operates on the same axis at 5-10 mg per dose.
Monoamine and neurotrophic effects
Epithalon's downstream effects on monoamine systems (dopamine, serotonin, occasionally noradrenaline) and on neurotrophic signalling (BDNF, NGF, NT-3) form the molecular substrate of its observed cognitive phenotype. Identified by Khavinson in St. Petersburg. Stimulates telomerase activity in somatic cells, with downstream effects on telomere length over multi-year cycles. Normalises age-related decline in pineal melatonin output. Putative epigenetic effects on aging-clock methylation patterns are an active area of investigation. For users tracking cognitive endpoints over the typical 1x daily for 10-20 day cycles, 1-2x yearly dosing pattern at 5-10 mg, the changes accumulate across 4–8 weeks rather than emerging acutely. The relevant clinical endpoints are sleep quality, recovery capacity, mood stability, and resilience to cognitive stressors.
Where Epithalon is used for post-tbi recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
Focus & Executive Function is one of the more-reported subjective benefits of Epithalon across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
For hpa axis modulation, Epithalon is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Where Epithalon is used for gut-brain axis, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 5-10 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 3-10 mg | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 5-10 mg | 1x daily for 10-20 day cycles, 1-2x yearly |
| Maintenance phase | SubQ | 4-10 mg | Ongoing with periodic pauses |
Dose timing for Epithalon is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Epithalon stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- Epithalon + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with Epithalon's mechanism in cognitive / neurological protocols.
- Epithalon + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with Epithalon's mechanism in cognitive / neurological protocols.
- Epithalon + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with Epithalon's mechanism in cognitive / neurological protocols.
- Epithalon + DSIP: Mechanism remains incompletely characterised. Pairs naturally with Epithalon's mechanism in cognitive / neurological protocols.
Outstanding safety profile in human studies extending to 15-year follow-up. No reported serious adverse events. Cycle-based dosing is standard.
Lens-specific safety considerations for cognitive / neurological use of Epithalon: Outstanding safety profile in human studies extending to 15-year follow-up. No reported serious adverse events. Cycle-based dosing is standard. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Epithalon | Pineal-derived tetrapeptide | Very short (minutes) | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
Is Epithalon appropriate alongside SSRIs or other psychiatric medications?
Can Epithalon be stacked with other nootropics?
How long until I notice cognitive effects?
Cognitive side effects to watch for?
What does Epithalon stack well with?
Is Epithalon a stimulant or a restorative?
Start a Epithalon Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified Epithalon and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- 390 Da
- Sequence length
- 4 aa
- Half-life
- Very short (minutes)
- WADA
- Not specifically listed
- FDA
- Unapproved
- Research
- Multi-decade Russian research; long-running human cohort studies
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Epithalon unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for Epithalon
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised